Panolos Bioscience, a biopharmaceutical company focused on the development of multi-specific therapeutics to treat cancer, auto-immune diseases and rare diseases, has entered into a collaboration with Chime Biologics, a CDMO, for a novel multi-specific protein drug, PB203, for solid tumors (PDAC/ICC), which is in the preclinical stage with plans to conduct a Phase I trial in the U.S.

Chime Biologics will provide CMC services for the development and manufacture of PB203 from cell line development, process development, and GMP manufacturing. It will be based on Chime’s CHOrus platform, which has a highly productive, rapid, and stable cell line development capability to select the optimal stable expression clones based on expression titer and quality.

HyeSeong Lim, Founder and CEO of Panolos Bioscience, said, “We are pleased to be a global strategic partner with Chime Biologics, and the co-development of PB203 is an important start in establishing our long-term strategic cooperation in Wuhan, China, covering commercial manufacturing. This is the first step in our shared mission to the commercialization of innovative medicines, starting from China and spreading to the world. By partnering with global CDMO Chime Biologics, we will do our best to bring hope and a new life to our patients.”

Jimmy Wei, President of Chime Biologics, said, “We are very excited to work with Panolos Bioscience to drive the project to Wuhan, China, taking unique advantage of Chime’s CHOrus cell line development platform that enables the U.S. clinical trials and global sampling. This is not only a recognition of Chime Biologics’ new business model and international quality system, but also an important development journey for Chime Biologics to go global. We believe that Chime Biologics’ high-quality platform and rich experience will facilitate the global R&D, clinical trials and future commercial manufacturing of multi-specific therapeutic proteins.”